Oral 3-Drug Combo Looks Promising in Treatment-Resistant Myeloma
Combining three well-known oral drugs shows potential for heavily pretreated multiple myeloma patients who have grown resistant to therapy with one of the included drugs, according…
Myeloma
Kyprolis Combo Seen to Improve Life Quality in Relapsed Multiple Myeloma Patients
Adding the proteasome inhibitor Kyprolis (carfilzomib) to the standard two-drug regimen of Revlimid (lenalidomide) and dexamethasone significantly improves health-related quality of life in relapsed multiple…
Phase 3 Trial Will Assess Darzalex-containing Combo Therapy in Multiple Myeloma Patients
The anti-CD38 agent Darzalex (daratumumab) will be investigated in a Phase 3 clinical trial in combination with Kyprolis (carfilzomib) and Decadron (dexamethasone) in relapsed/refractory multiple…
FDA Places Hold on BioInvent’s Phase 2 Trial for Multiple Myeloma Therapy
The U.S. Food and Drug Administration (FDA) has verbally notified BioInvent International that it’s placing a full clinical hold on the company’s Phase 2 trial evaluating…
Karyopharm to Present Updated Clinical Data of Selinexor in Multiple Myeloma Patients
Karyopharm Therapeutics is set to present novel clinical data on its lead product candidate selinexor, an oral selective inhibitor of nuclear export compound that…
MorphoSys to Present Proprietary Hemato-Oncological Antibody Programs at ASH 2016
MorphoSys, the creator of HuCAL (Human Combinatorial Antibody Library), will give two oral and one poster presentation on the company’s proprietary antibody hemato-oncological programs, MOR208 and…
Genentech to Present Data From Multiple Clinical Trials on Myeloma and Other Blood Cancers
Genentech will present results on several approved or investigational therapies for blood cancers, including lymphoma and myeloma, in the upcoming 58th American Society…
Clinical Trial Will Assess Immunotherapy Combo in Multiple Myeloma Patients in 2017
Adaptimmune Therapeutics and Merck have agreed to begin a clinical trial next year assess the safety and efficacy of combining the anti-PD-1 inhibitor Keytruda…
Multiple Myeloma Patients Treated at Higher-volume Facilities Have Better Outcomes, Study Finds
Patients treated for multiple myeloma at facilities that see a higher number of multiple myeloma patients annually had better outcomes compared to patients who were treated at…
Longer Revlimid Maintenance after Stem Cell Transplant Prolongs Myeloma Patient Survival
Longer duration of maintenance therapy with Revlimid (lenalidomide) after autologous hematopoietic stem cell transplantation (HSCT) prolongs survival for multiple myeloma patients without increasing…
Recent Posts
- Germany clears pelareorep pancreatic cancer trial continuation
- FDA grants orphan drug status to novel brain cancer treatment
- Medicaid expansion can raise demand for gynecologic cancer care
- Under-the-skin Sarclisa found as effective as approved formulation
- FDA gives LYT-200 fast track status as potential AML treatment